Avon SEC settlement
This article was originally published in The Rose Sheet
Executive Summary
Avon enters settlement agreement with Securities and Exchange Commission regarding 1999 accounting write-off related to an aborted initiative to develop customized order management system. Under the settlement, announced July 17, Avon will restate its first quarter 1999 results by lowering reported earnings per share by 5 cents, and restate third quarter 2001 results with EPS increase of 6 cents. Company recorded partial write-off of approximately $15 mil. for the software system in the first quarter of 1999 and wrote off the remaining $24 mil. in the third quarter of 2001. Costs consisted mainly of professional service fees paid to Coopers & Lybrand, PricewaterhouseCoopers. SEC determined entire software value should have been written off in the first quarter of 1999. Settlement did not involve any penalty or fine...
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.